H von der Maase

Summary

Affiliation: Aarhus University Hospital
Country: Denmark

Publications

  1. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
  2. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
  3. ncbi Gemcitabine in transitional cell carcinoma of the urothelium
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, Denmark
    Expert Rev Anticancer Ther 3:11-9. 2003
  4. ncbi Pemetrexed in transitional cell carcinoma of the urothelium
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Oncology (Williston Park) 18:48-50. 2004
  5. ncbi [Urinary bladder cancer]
    Hans von der Maase
    Arhus Universitetshospital, Arhus Kommunehospital, Onkologisk afdeling
    Ugeskr Laeger 164:3052-6. 2002
  6. ncbi Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer
    H von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 C, Aarhus, Denmark
    Eur J Cancer 36:13-6. 2000
  7. ncbi Gemcitabine in locally advanced and/or metastatic bladder cancer
    H von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 C, Aarhus, Denmark
    Crit Rev Oncol Hematol 34:175-83. 2000
  8. ncbi Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity
    R Zachariae
    Psychooncology Research Unit, Department of Oncology, Aarhus University Hospital, and Institute of Psychology, University of Aarhus, Aarhus, Denmark
    Psychother Psychosom 76:376-84. 2007
  9. ncbi Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study
    H Schmidt
    Department of Oncology, Aarhus University Hospital, Denmark
    Melanoma Res 10:66-77. 2000
  10. ncbi Effect of chemotherapy on carcinoma in situ of the testis
    T B Christensen
    Department of Oncology, Aarhus University Hospital, Denmark
    Ann Oncol 9:657-60. 1998

Detail Information

Publications82

  1. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
    ..To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC)...
  2. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
    ..Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium...
  3. ncbi Gemcitabine in transitional cell carcinoma of the urothelium
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, Denmark
    Expert Rev Anticancer Ther 3:11-9. 2003
    ..Thus, GC is now considered a standard of care for patients with locally advanced and metastatic urothelial cancer. Other promising combinations include gemcitabine together with one of the taxanes with or without cisplatin...
  4. ncbi Pemetrexed in transitional cell carcinoma of the urothelium
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Oncology (Williston Park) 18:48-50. 2004
    ..Further investigation of combinations of pemetrexed and other active drugs in the treatment of patients with locally advanced and metastatic disease is warranted...
  5. ncbi [Urinary bladder cancer]
    Hans von der Maase
    Arhus Universitetshospital, Arhus Kommunehospital, Onkologisk afdeling
    Ugeskr Laeger 164:3052-6. 2002
  6. ncbi Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer
    H von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 C, Aarhus, Denmark
    Eur J Cancer 36:13-6. 2000
    ..This promising two-drug combination has been compared with the standard MVAC regimen (methotrexate, vinblastine, doxorubicin, and cisplatin) in a randomised phase III trial and the results are eagerly anticipated...
  7. ncbi Gemcitabine in locally advanced and/or metastatic bladder cancer
    H von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 C, Aarhus, Denmark
    Crit Rev Oncol Hematol 34:175-83. 2000
    ..Preliminary results for gemcitabine tested in two- and three-drug combinations with new agents such as paclitaxel have indicated response rates of up to 79% and these combinations should be further explored...
  8. ncbi Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity
    R Zachariae
    Psychooncology Research Unit, Department of Oncology, Aarhus University Hospital, and Institute of Psychology, University of Aarhus, Aarhus, Denmark
    Psychother Psychosom 76:376-84. 2007
    ..The aim of our study was to investigate the role of individual differences related to sensory perception for posttreatment side effects...
  9. ncbi Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study
    H Schmidt
    Department of Oncology, Aarhus University Hospital, Denmark
    Melanoma Res 10:66-77. 2000
    ..This high dose interleukin-2 subcutaneous regimen resulted in a small fraction of long-term survivors. The response and survival results were not superior to other studies using lower and less toxic interleukin-2 doses...
  10. ncbi Effect of chemotherapy on carcinoma in situ of the testis
    T B Christensen
    Department of Oncology, Aarhus University Hospital, Denmark
    Ann Oncol 9:657-60. 1998
    ..CIS will progress into invasive tumour in about 50% of cases within five years. The present study evaluated the effect of platinum containing chemotherapy on CIS...
  11. pmc Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial
    F Donskov
    Department of Oncology, Aarhus University Hospital, Denmark
    Br J Cancer 94:218-26. 2006
    ....
  12. ncbi Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma
    H Schmidt
    Department of Oncology, Aarhus University Hospital, Denmark
    Melanoma Res 12:585-92. 2002
    ..However, these conversions did not significantly correlate with objective response. The presence of TYR mRNA in one of the first two samples showed a trend towards being an independent prognostic factor for poor survival...
  13. pmc In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma
    F Donskov
    Department of Oncology, Aarhus University Hospital, Denmark
    Br J Cancer 90:626-31. 2004
    ..These data suggest that IFN-alpha in vivo has only modest effect on tumour proliferation in patients with mRCC. Tumour Ki-67 (MIB-1) reactivity after 1 month of immunotherapy appears to be a significant predictor of patient survival...
  14. ncbi A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium
    H von der Maase
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    Ann Oncol 17:1533-8. 2006
    ....
  15. ncbi A new quantitative RT-PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls
    E Ehrnrooth
    Department of Oncology, Aarhus University Hospital, Denmark
    Clin Chim Acta 290:129-44. 2000
    ..This new CURT-PCR assay may allow improved studies of functional kinetics of drugs with impact upon TS. Further studies are required to establish the possible clinical benefit of TS mRNA measurements in blood leukocytes...
  16. pmc Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma
    F Donskov
    Department of Oncology, Aarhus University Hospital, Denmark
    Br J Cancer 93:757-62. 2005
    ..Only three patients had grade 4 toxicity; however, two were fatal. A randomised phase III trial is warranted to clarify the potential role of adding histamine to IL-2 in mRCC...
  17. pmc Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model
    H Schmidt
    Department of Oncology, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark
    Br J Cancer 93:273-8. 2005
    ..4 months (95% CI, 1.2-5.6), respectively. The low-risk group encompassed the majority of long-term survivors, whereas the patients in the high-risk group with a very poor prognosis should probably not be offered IL-2-based immunotherapy...
  18. pmc Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans
    T B Christensen
    Department of Oncology, Aarhus University Hospital, Denmark
    Br J Cancer 80:1582-7. 1999
    ..v. Thus, information about the expected elimination of hCG can be obtained by following the elimination of activity in plasma after injection of 125I-hCG...
  19. pmc Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival
    F Donskov
    Department of Oncology, Aarhus University Hospital, Denmark
    Br J Cancer 87:194-201. 2002
    ..Confirmation of the results requires further studies including a larger number of patients...
  20. pmc Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
    P F Geertsen
    Department of Oncology, University of Copenhagen in Herlev Hospital, Amtssygehuset i Herlev, Denmark
    Br J Cancer 90:1156-62. 2004
    ..c. and c.i.v. administration of rIL-2 in terms of overall survival, duration of response and response rate in patients with metastatic renal cell carcinoma. However, s.c. delivery of rIL-2 was associated with improved tolerability...
  21. ncbi Gemcitabine in advanced bladder cancer
    H von der Maase
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Semin Oncol 28:11-4. 2001
    ..Semin Oncol 28 (suppl 7):11-14...
  22. ncbi Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years
    L Sengeløv
    Department of Oncology, Herlev University Hospital, Copenhagen, Denmark
    Eur Urol 39:634-42. 2001
    ..We have furthermore investigated changes in patient characteristics and treatment strategies during the last 20 years...
  23. ncbi Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil
    E Ehrnrooth
    Department of Oncology, Aarhus University Hospital, Denmark
    Acta Oncol 39:53-7. 2000
    ..The present results indicate that TS mRNA in blood leukocytes may be an early indicator of an RNA damaging effect after i.v. bolus infusion of 5-FU...
  24. ncbi A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma
    H Schmidt
    Department of Oncology, Aarhus University Hospital, Denmark
    Ann Oncol 13:1919-24. 2002
    ..Experimental data had suggested a synergistic effect of histamine with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha)...
  25. ncbi The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo
    E Ehrnrooth
    Department of Oncology, Aarhus University Hospital, Denmark
    Int J Radiat Biol 75:885-91. 1999
    ..Hypoxic cells in tumours are resistant to 5-fluorouracil (5-FU). This in vivo study investigated the ability of hypoxia to regulate the gene expression of thymidylate synthase (TS), the target enzyme of 5-FU...
  26. ncbi Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies
    Anne Birgitte Als
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Eur Urol 52:478-86. 2007
    ....
  27. pmc Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer
    M Agerbaek
    Department of Oncology, Aarhus University Hospital, Norrebrogade 44, DK8000 Aarhus C, Denmark
    Br J Cancer 89:298-304. 2003
    ..Loss of pRB expression seems to indicate a phenotype displaying enhanced radiosensivity and may be of benefit by denoting patients who would selectively benefit from a treatment schedule containing radiotherapy...
  28. pmc Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma
    A N Jeppesen
    Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark
    Br J Cancer 102:867-72. 2010
    ..Low serum sodium has recently been associated with poor survival in localised renal cell carcinoma (RCC). We now show the prognostic effect of serum sodium in patients with metastatic RCC (mRCC)...
  29. ncbi Current and future perspectives in advanced bladder cancer: is there a new standard?
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Semin Oncol 29:3-14. 2002
    ..An international phase III trial comparing this triple combination with GC in patients with locally advanced and metastatic urothelial cancer has now been initiated...
  30. ncbi Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours
    Lisa Sengeløv
    Department of Oncology, University Hospital Herlev, Copenhagen, Denmark
    Acta Oncol 41:447-56. 2002
    ..Neoadjuvant chemotherapy with cisplatin and methotrexate did not significantly improve disease-free or overall survival in 153 randomized patients with invasive bladder cancer...
  31. doi Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy
    Christian Jessen
    Department of Oncology, Aarhus University Hospital, Aarhus Sygehus, Nørrebrogade 44, Aarhus C, Denmark
    Acta Oncol 48:411-7. 2009
    ....
  32. ncbi S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus, Denmark
    Melanoma Res 14:211-5. 2004
    ....
  33. ncbi Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
    Anne Birgitte Als
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Acta Oncol 47:110-9. 2008
    ..However, an alternative 3-week schedule may be more feasible. Long-term survival data for the alternative 3-week schedule and comparisons of the feasibility and toxicity between the two schedules have not previously been published...
  34. ncbi Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer
    Lars Fokdal
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Acta Oncol 43:749-57. 2004
    ..Three patients (1%) were cystectomized because of severe radiation reactions in the bladder. At 5-year follow-up, the actuarial risk of complications requiring surgery was 15%. Treatment-related mortality was 2%...
  35. ncbi A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma
    Akmal Safwat
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Radiother Oncol 77:143-7. 2005
    ..Our own experimental data suggests a therapeutic synergism between low-dose total body irradiation (LTBI) and interleukin-2 (IL-2)...
  36. ncbi Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 25:1562-9. 2007
    ..In this study, we aimed to validate this finding in a large cohort of stage IV melanoma patients...
  37. doi Sexuality and body image in long-term survivors of testicular cancer
    P Rossen
    Department of Oncology, Aarhus University Hospital, Denmark
    Eur J Cancer 48:571-8. 2012
    ..This study explores sexual function and the influence of different treatment modalities on sexual function and body image among long-term survivors of testicular cancer (TCSs)...
  38. ncbi A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma
    M Overgaard
    Department of Oncology, Aarhus University Hospital, Denmark
    Acta Oncol 32:547-53. 1993
    ..However, addition of the drug resulted in an apparent increase in the frequency of severe acute radiation complications (33% vs. 13% after irradiation alone)...
  39. pmc 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer
    T B Christensen
    Department of Oncology, Aarhus University Hospital, Denmark
    Br J Cancer 80:1577-81. 1999
    ..Difficulties in interpreting a slow decline of hCG may be overcome by comparing the plasma disappearance of total hCG with the plasma disappearance of [125I]hCG...
  40. ncbi Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy
    Henrik Schmidt
    Department of Oncology bClinical Biochemistry, NBG, Aarhus University Hospital, Aarhus, Denmark
    Melanoma Res 15:409-16. 2005
    ..Additional studies are needed before the prognostic value of tyrosinase mRNA in metastatic melanoma can be firmly established. Further evaluation of the combined measurement of tyrosinase mRNA and LDH is warranted...
  41. ncbi Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack
    Frede Donskov
    Department of Oncology, Aarhus University Hospital, Norrebrograde, Aarhus, 8000, Denmark
    Clin Cancer Res 10:7911-6. 2004
    ..We assessed the effect of FasL tumor counterattack on the clinical outcome of interleukin-2 (IL-2)-based immunotherapy in metastatic renal cell carcinoma...
  42. ncbi Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer
    Anne B Als
    Department of Oncology, Aarhus University Hospital, Denmark
    Clin Cancer Res 13:4407-14. 2007
    ..The response rate is approximately 50% and tumor-derived molecular prognostic markers are desirable for improved estimation of response and survival...
  43. ncbi Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity
    R Zachariae
    Psychooncology Research Unit, Department of Oncology, Aarhus University Hospital, and Institute of Psychology, University of Aarhus, Denmark
    Ann Behav Med 33:69-79. 2007
    ..Anticipatory nausea (AN) during chemotherapy has been difficult to control with conventional antiemetics. AN can lead cancer patients to delay or discontinue chemotherapy, possibly compromising the treatment...
  44. ncbi Impact of immune parameters on long-term survival in metastatic renal cell carcinoma
    Frede Donskov
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 24:1997-2005. 2006
    ..The purpose of this study was to evaluate the impact of immunologic prognostic factors in combination with established clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC)...
  45. ncbi Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    J Invest Dermatol 126:849-54. 2006
    ..The serial measurements of tyrosinase and MART-1 mRNA in peripheral blood of stage I-II melanoma patients cannot be demonstrated to have independent prognostic impact on relapse-free survival...
  46. ncbi Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients
    Morten Ladekarl
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus, Denmark
    Cancer Immunol Immunother 53:560-6. 2004
    ..The lysate was produced from a melanoma cell line (FM3.29) which expresses high amounts of melanoma antigens...
  47. ncbi Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark
    J Clin Oncol 24:798-804. 2006
    ..Macrophages, neutrophils, and cancer cells secrete YKL-40, and a high serum level has been associated with poor prognosis in patients with several cancer types...
  48. ncbi Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study
    F Donskov
    Department of Oncology, Aarhus University Hospital, Denmark
    Ann Oncol 13:441-9. 2002
    ..Efficacy and safety of histamine, when given in combination with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha), were evaluated in patients with metastatic renal cell carcinoma (mRCC)...
  49. doi Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma
    Hanne Krogh Jensen
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    BJU Int 101:41-4. 2008
  50. ncbi Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients
    Mads Agerbaek
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Eur Urol 50:777-85. 2006
    ..The purpose of the present study was to investigate the prognostic potential of S100A4 protein expression for predicting distant metastatic relapse in muscle-invasive bladder cancer...
  51. ncbi Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Denmark
    Cancer 106:1130-9. 2006
    ..Its function in cancer is unknown. High serum YKL-40 levels have been associated with a poor prognosis in patients with several solid tumors. The prognostic impact of serum YKL-40 in metastatic melanoma was evaluated...
  52. ncbi Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen
    Hans von der Maase
    Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Eur Urol 52:1122. 2007
  53. doi Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma
    Hanne Krogh Jensen
    Department of Oncology and Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, Aarhus C, Denmark
    Clin Cancer Res 15:1052-8. 2009
    ..The impact of IL-2-based therapy on the accumulation of FOXP3-positive immune cells in the tumor microenvironment in metastatic renal cell carcinoma is unknown...
  54. ncbi Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
    Morten Hoyer
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Radiother Oncol 76:48-53. 2005
    ..Stereotactic radiotherapy (SRT) may be an alternative treatment for patients with locally advanced disease. The effect of SRT was investigated in the present phase-II trial...
  55. doi Health-related quality of life in long-term survivors of testicular cancer
    Philip Blach Rossen
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    J Clin Oncol 27:5993-9. 2009
    ..A growing number of patients with testicular cancer (TC) become long-term survivors. As a consequence, quality-of-life (QOL) issues become increasingly important. The objective of this study was to investigate QOL among Danish TC survivors...
  56. doi Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer
    Søren Christensen
    Psychooncology Reseach Unit, Aarhus University Hospital, Nobelparken, Bygn 1483, 8000, Aarhus C, Denmark
    Breast Cancer Res Treat 113:339-55. 2009
    ..Elevated levels of depressive symptoms are generally found among cancer patients, but results from existing studies vary considerably with respect to prevalence and proposed risk factors...
  57. ncbi Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma
    Lone Duval
    Department of Oncology, Aarhus University Hospital, Denmark
    Clin Cancer Res 12:1229-36. 2006
    ....
  58. ncbi Phase II study on stereotactic body radiotherapy of colorectal metastases
    Morten Hoyer
    Department of Oncology, Aarhus University Hospital
    Acta Oncol 45:823-30. 2006
    ..One toxic death and few severe reactions were observed. For the majority of patients, the treatment related toxicity was moderate...
  59. ncbi Radical radiotherapy for urinary bladder cancer: treatment outcomes
    Lars Fokdal
    Department of Oncology, Aarhus University Hospital, DK 8000 C Aarhus, Denmark
    Expert Rev Anticancer Ther 6:269-79. 2006
    ..An estimate of the 5-year overall survival rate following radiotherapy is approximately 35% in consecutive-selected patients and approximately 25% in negative-selected patients...
  60. ncbi Increased thymidylate synthase mRNA concentration in blood leukocytes following an experimental stressor
    Eva Ehrnrooth
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Psychother Psychosom 71:97-103. 2002
    ....
  61. ncbi Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy
    Lars Fokdal
    Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, DK 8000 Aarhus, Denmark
    Radiother Oncol 74:203-10. 2005
    ..To correlate long-term colorectal dysfunctions following radical radiotherapy for bladder or prostate cancer with clinical parameters and dose-volume histogram parameters of the small intestine, rectum, and anal canal volume...
  62. ncbi High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors
    Karen Koed
    Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
    Cancer Res 65:34-45. 2005
    ..05). These data show the power of high-resolution SNP arrays for defining clinically relevant AIs...
  63. ncbi [Immunotherapy of cancer]
    Mads Hald Andersen
    Kraeft Immunologisk Forskningsgruppe, Institut for Biologisk Kraeftforskning, Kraeftens Bekaempelse, DK 2100, København Ø
    Ugeskr Laeger 164:3008-16. 2002
    ..Further, novel methodologies for monitoring and analysing cancer patients over the course of immunotherapeutic treatments are described, and future directions put forward...
  64. ncbi Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy
    Bettina Dencker Hansen
    Institute of Medical Microbiology and Immunology, University of Aarhus, Denmark
    Acta Oncol 45:400-5. 2006
    ..Our data suggest that tumour-associated macrophages may correlate negatively with response, which may be of biological importance for IL-2 based immunotherapy of malignant melanoma...
  65. ncbi [Malignant skin melanoma]
    Krzysztof T Drzewiecki
    Plastik og brandsårsafdelingen, H S Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 164:3031-5. 2002
  66. ncbi Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma
    Frede Donskov
    Institute of Medical Microbiology and Immunology, University of Aarhus, Denmark
    Cancer Immunol Immunother 53:729-39. 2004
    ..No discernable differences in immunologic parameters studied could be detected between histamine- and nonhistamine-treated patients...
  67. ncbi Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer
    Walter M Stadler
    University of Chicago, Department of Medicine, 5841 S Maryland, MC2115, Chicago, Illinois 60637, USA
    Urol Oncol 7:153-7. 2002
    ..To assess long-term survival and prognostic indicators of survival in patients with advanced urothelial cancer treated with gemcitabine and cisplatin...
  68. ncbi A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
    Jonathan E Rosenberg
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Cancer 103:2035-41. 2005
    ..R115777 is a potent farnesyl transferase inhibitor and has significant antitumor effects in vitro and in vivo...
  69. ncbi Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
    Cora N Sternberg
    Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Urology 69:62-79. 2007
    ....
  70. ncbi Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays
    Hanne Primdahl
    Molecular Diagnostic Laboratory and Department of Clinical Biochemistry, Aarhus University Hospital at Skejby, Denmark
    J Natl Cancer Inst 94:216-23. 2002
    ..In this study, we investigated whether genome-wide screening using single-nucleotide polymorphism (SNP) arrays could detect allelic imbalance (loss or gain of at least one allele) in bladder cancers...
  71. ncbi Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis
    Peter Meidahl Petersen
    Department of Growth and Reproduction, Finsencenter, Copenhagen University Hospital, Rigshospitalet, Copenhagen
    J Clin Oncol 20:1537-43. 2002
    ..To determine the effect of radiotherapy in doses 14 to 20 Gy on eradication of carcinoma-in-situ (CIS) testis and on the Leydig cell function...
  72. ncbi Serum lactate dehydrogenase isoenzyme 1 in patients with seminoma stage I followed with surveillance
    Finn Edler von Eyben
    Department of Clinical Chemistry Odense University Hospital, Denmark
    Acta Oncol 41:77-83. 2002
    ..Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I...
  73. ncbi Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer
    Hanne Primdahl
    Department of Clinical Biochemistry, Aarhus University Hospital at Skejby, Aarhus N, Denmark
    J Cancer Res Clin Oncol 128:295-301. 2002
    ..The cell cycle is known to be deregulated in cancer. We therefore analyzed the expression of the cell cycle related proteins p21, p27, p16, Rb, and L-myc by immunohistochemical staining of bladder tumors...
  74. ncbi [Oncologic treatment]
    Hans von der Maase
    Ugeskr Laeger 164:2999. 2002
  75. doi European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:478-96. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands...
  76. doi European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:497-513. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands...
  77. ncbi Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure?
    Hans von der Maase
    Acta Oncol 44:523-5. 2005
  78. ncbi [Chemotherapy as a supplement to radical treatment of patients with locally advanced bladder cancer]
    Lisa Sengeløv
    Amtssygehuset i Herlev, Onkologisk afdeling
    Ugeskr Laeger 167:749-51. 2005
  79. ncbi [Testicular cancer]
    Kirsten Gedske Daugaard
    Onkologisk Klinik 5073, Finsencentret, H S Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 164:3063-7. 2002
  80. ncbi Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:4448-52. 2002
    ..We performed a pooled analysis of patients from the four largest surveillance studies to better delineate prognostic factors associated with disease progression...
  81. ncbi [Renal cancer--a new clearing report]
    Hans Colstrup
    Ugeskr Laeger 164:5359. 2002
  82. ncbi The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma
    Micaela Hernberg
    Department of Oncology, HUSLAB, Helsinki University Central Hospital, Finland
    J Immunother 30:773-9. 2007
    ..Our data show that both the proportions of CD3+CD4+CD69+ cells and of CD3+CD56+ cells seem to have a prognostic potential in the natural course of melanoma. These results need to be confirmed in larger studies...